Analyst Kallum Titchmarsh from Morgan Stanley maintained a Buy rating on Inspire Medical Systems (INSP – Research Report) and decreased the price target to $220.00 from $230.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Kallum Titchmarsh has given his Buy rating due to a combination of factors that highlight Inspire Medical Systems’ strong performance and potential for growth. Despite the civil investigative demand from the DOJ concerning their marketing and reimbursement practices, which could cause short-term market fluctuations, Titchmarsh believes the company’s financial position is solid enough to manage these challenges. With a robust cash and investment balance, Inspire Medical Systems is well-positioned to handle any outcomes related to the investigation.
Moreover, the company’s recent financial results demonstrate impressive growth, with revenues exceeding expectations both in the US and internationally. Inspire Medical Systems continues to outperform below the topline, and its stock is trading at a discount compared to peers, offering a compelling investment opportunity. The anticipated full launch of Inspire V in 2025, combined with conservative guidance, suggests consistent performance and potential for future revenue increases, underpinning Titchmarsh’s positive outlook and Buy rating.